SEC Form 4 · accession 0001179110-17-001932
ENDOCYTE INC · ECYT
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Philip S Low
Officer — Chief Science Officer · Director
Period of report
Feb 4, 2017
Accepted (ET)
Feb 7, 2017 · 7:25 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001235007
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Feb 4, 2017 | F | 1,888 | $2.18 | D | 249,299 | D | |
| Common StockF2 | Feb 6, 2017 | F | 694 | $2.18 | D | 248,605 | D | |
| Common Stock | holding | — | — | — | 193,318 | I | By spouse trust |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Represents shares withheld to satisfy tax withholding obligations associated with the settlement of 2,916 and 2,187 restricted stock units in the form of Company common stock on a one-for-one basis on February 4, 2017.
- F2Represents shares withheld to satisfy tax withholding obligations associated with the settlement of 1,875 restricted stock units in the form of Company common stock on a one-for-one basis on February 6, 2017.